NRX Pharmaceuticals Warrant
NRXPW
NRXPW was delisted on the 22nd of May, 2026.
5 hedge funds and large institutions have $2.74M invested in NRX Pharmaceuticals Warrant in 2021 Q1 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 0 reducing their positions, and 0 closing their positions.
315% more capital invested
Capital invested by funds: $661K → $2.74M (+$2.08M)
150% more funds holding
Funds holding: 2 → 5 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
CAAS Capital Management
New York
|
+$543K |
| 2 |
ICM
Ionic Capital Management
New York
|
+$164K |
| 3 |
AC
Athanor Capital
New York
|
+$122K |
Top Sellers
NRXPW Hedge Fund Activity: Q1 2021 in Review
5 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q1 2021, worth a combined $2.74M — up 315% from $661K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new NRXPW positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was CAAS Capital Management, opening a new position worth an estimated $543K.
- 5 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q1 2021, up from 2 in Q4 2020.
- Funds reported $2.74M of NRX Pharmaceuticals Warrant stock for Q1 2021, up 315% quarter-over-quarter.
- 3 funds opened new NRX Pharmaceuticals Warrant positions in Q1 2021 and 0 closed out, a net change of +3 holders.
- The largest NRX Pharmaceuticals Warrant buyer in Q1 2021 was CAAS Capital Management, an estimated $543K added.
Based on aggregated 13F filings for Q1 2021.